SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1503)10/23/1998 10:24:00 PM
From: arnie h  Read Replies (2) | Respond to of 2173
 
Rudy: Your post noted that Amylin's finances are none. Just wondering if you are able to quantify this further. Does none truly mean none or is there enough to last 3,6 or more months if they continue with US trials? Their PR seemed to imply that laying off 75% of their staff would enable them to continue at least for a while. I'd be interested in whatever quantitative comments you might have. Thanks,

Arnie



To: Rudy Saucillo who wrote (1503)10/24/1998 9:08:00 AM
From: Rudy Saucillo  Respond to of 2173
 
Oops! Now *that's* a Freudian slip. I'm sure I'll be writing a similar comment in a month or two about pimagidine. But obviously I was referring to pramlintide in this post. Rudy



To: Rudy Saucillo who wrote (1503)10/24/1998 11:19:00 AM
From: David Bogdanoff  Read Replies (2) | Respond to of 2173
 
RS;

The planning and subsequent modification of the clinical trials is typical of pharmaceutical industry practice, for better or worse. It did not signal to me a reason for lack of confidence in the company. BTW, if the trials were poorly planned, how do you know the product has no commercial value? Poorly planned trials don't prove much of anything.

David


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News